Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study

被引：0

作者：

Knauf, Wolfgang ^{[1
]}

Uhlig, Jens ^{[2
]}

von der Heyde, Eyck ^{[3
]}

Losem, Christoph ^{[4
]}

Ammon, Andreas ^{[5
]}

Nusch, Arnd ^{[6
]}

Schlag, Rudolf ^{[7
]}

Schulz, Holger ^{[8
]}

Janssen, Jan ^{[9
]}

Welslau, Manfred ^{[10
]}

Wilop, Stefan ^{[11
]}

Vannier, Corinne ^{[12
]}

Siebenbach, Hans Ulrich ^{[12
]}

Serrer, Laura ^{[12
]}

Schuch, Anita ^{[12
]}

Woerner, Sandra Maria ^{[12
]}

Engelhardt, Monika ^{[13
]}

Potthoff, Karin ^{[12
]}

机构：

[1] Ctr Hamatol & Onkol Bethanien, Frankfurt, Germany

[2] Praxis Dr Med Jens Uhlig, Naunhof, Germany

[3] Onkol Schwerpunktpraxis, Hannover, Germany

[4] Rheinlandklinikum, Grevenbroich, Germany

[5] OSP Gottingen, Gottingen, Germany

[6] Praxis Hamatol & Internist Onkol, Ratingen, Germany

[7] Hamatol Onkol Schwerpunktpraxis Wurzburg, Wurzburg, Germany

[8] Praxis Internist Onkol & Hamatol PIOH, Frechen, Germany

[9] Gemeinschaftspraxis Hamatol & Onkol, Westerstede, Germany

[10] MVZ Klinikum Aschaffenburg, Aschaffenburg, Germany

[11] MVZ West GmbH Wurselen Hamatol Onkol, Wurselen, Germany

[12] iOMEDICO, Ellen Gottlieb Str 19, D-79106 Freiburg, Germany

[13] Univ Freiburg, Bernstein Ctr Freiburg, Freiburg, Germany

来源：

LEUKEMIA & LYMPHOMA | 2025年 / 66卷 / 04期

关键词：

Carfilzomib; chemotherapeutic approaches; antibody-based immunotherapy; myeloma; OPEN-LABEL; DEXAMETHASONE; LENALIDOMIDE; DARATUMUMAB; NONADHERENCE; MULTICENTER; MORTALITY; SURVIVAL; OUTCOMES; RATES;

D O I：

10.1080/10428194.2024.2436034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Therapy adherence can significantly influence the outcome of cancer patients. The prospective, non-interventional CARO study (NCT02970747) investigated adherence, effectiveness, and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) in the German real-world setting. In total, 359 patients were included at 69 sites. Data on carfilzomib combination regimens were evaluated for three treatment cohorts: carfilzomib with lenalidomide and dexamethasone (KRd), with dexamethasone only (Kd) or with daratumumab and dexamethasone (KdD). Encouragingly, patients maintained levels of treatment adherence >= 95% to carfilzomib across cohorts. The effectiveness outcomes of CARO were in line with previous data. Median PFS (95% CI) was 17.5 months (14.5, 24.7 [KRd]), 13.4 months (7.0, 18.1 [Kd]), and 15.6 months (9.9, NA [KdD]), respectively. Median OS was 38.9 months (31.5, 53.9 [KRd]), 24.2 months (17.3, 36.8 [Kd]), and not reached (KdD). Overall, the CARO study impressively demonstrates efficacy and safety of KRd, Kd, and KdD regimen in real-world.

引用

页码：691 / 701

页数：11

共 42 条

[1]

[Anonymous], 2018, KYPROLIS SUMMARY PRO

[2] Adherence to Adjuvant Therapy in Patients with Resected Melanoma: An Application of the Theory of Planned Behavior [J].

Beisel, Cassie ;

Poretta, Tayla ;

Sheppard, Vanessa B. ;

Hurtado-de Mendoza, Alejandra ;

Sipsma, Heather ;

Fuqua, Eleanore ;

Stwalley, Brian ;

Salvatore, Anthony ;

Yang, Min .

ADVANCES IN THERAPY, 2022, 39 (09) :4061-4075

[3] Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials [J].

Chari, Ajai ;

Stewart, A. Keith ;

Russell, Stuart D. ;

Moreau, Philippe ;

Herrmann, Joerg ;

Banchs, Jose ;

Hajek, Roman ;

Groarke, John ;

Lyon, Alexander R. ;

Batty, George N. ;

Ro, Sunhee ;

Huang, Mei ;

Iskander, Karim S. ;

Lenihan, Daniel .

BLOOD ADVANCES, 2018, 2 (13) :1633-1644

[4]

Common Terminology Criteria for Adverse Events (CTCAE), 2017, CTCAE4032010 06 14QU

[5] Adherence to immunomodulatory drugs in patients with multiple myeloma [J].

Cransac, Amelie ;

Aho, Serge ;

Chretien, Marie-Lorraine ;

Giroud, Maurice ;

Caillot, Denis ;

Boulin, Mathieu .

PLOS ONE, 2019, 14 (03)

[6] Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro-prospective observational study [J].

Del Giudice, Maria Livia ;

Gozzetti, Alessandro ;

Antonioli, Elisabetta ;

Attucci, Irene ;

Pengue, Ludovica ;

Cassano Cassano, Raffaella ;

Ghio, Francesco ;

Orciuolo, Enrico ;

Simoncelli, Martina ;

Bocchia, Monica ;

Galimberti, Sara ;

Buda, Gabriele .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (04) :373-380

[7] Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma [J].

Dima, Danai ;

Mansour, Razan ;

Davis, James A. ;

Minchak, Megan ;

Goel, Utkarsh ;

Atallah, Rawan ;

Logan, Emerson ;

Tabak, Carine ;

Rashid, Aliya ;

Ahmed, Nausheen ;

Abdallah, Al-Ola ;

Hashmi, Hamza .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (06) :975-983

[8]

Dimopoulos M, 2020, LANCET, V396, P186, DOI 10.1016/S0140-6736(20)30734-0

[9] Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial [J].

Dimopoulos, Meletios A. ;

Goldschmidt, Hartmut ;

Niesvizky, Ruben ;

Joshua, Douglas ;

Chng, Wee-Joo ;

Oriol, Albert ;

Orlowski, Robert Z. ;

Ludwig, Heinz ;

Facon, Thierry ;

Hajek, Roman ;

Weisel, Katja ;

Hungria, Vania ;

Minuk, Leonard ;

Feng, Shibao ;

Zahlten-Kumeli, Anita ;

Kimball, Amy S. ;

Moreau, Philippe .

LANCET ONCOLOGY, 2017, 18 (10) :1327-1337

[10] How lenalidomide is changing the treatment of patients with multiple myeloma [J].

Dimopoulos, Meletios A. ;

Terpos, Evangelos ;

Niesvizky, Ruben .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 88 :S23-S35

← 1 2 3 4 5 →